Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nuvation BioNUVB -3.68%32 Debt-to-Equity is 0.99 as of Jun. 2026, which is 9800% above its 10-year median of 0.01. GuruFocus rates NUVB with a GF Score™ of 32/100. The stock has 5 warning signs investors should review. Among 962 Biotechnology companies, Nuvation Bio ranks worse than 87.84% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nuvation Bio's Debt-to-Equity or its related term are showing as below:
NUVB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.99
Current: 0.99
During the past 6 years, the highest Debt-to-Equity Ratio of Nuvation Bio was 0.99. The lowest was 0.00. And the median was 0.01.
NUVB's Debt-to-Equity is ranked worse than 87.84% of 962
companies
in the Biotechnology industry
Industry Median: 0.16
vs NUVB: 0.99
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nuvation Bio Debt-to-Equity Related Terms
Nuvation Bio Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nuvation Bio's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUVB vs RAPP, BHVN, KOD: Debt-to-Equity Comparison
For the Biotechnology subindustry, Nuvation Bio's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nuvation Bio Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nuvation Bio's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nuvation Bio's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nuvation Bio (NUVB) has a Debt-to-Equity of 0.99 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nuvation Bio and its competitors. This is 9800% above median its historical median of 0.01. According to the industry distribution chart, Nuvation Bio ranks #845 out of 962 companies in the Biotechnology industry, placing it in the top 87.8%.
Is Nuvation Bio's Debt-to-Equity too high?
Nuvation Bio's current Debt-to-Equity of 0.99 is 9800% above median its 10-year median of 0.01. The Biotechnology industry median Debt-to-Equity is 0.16. Nuvation Bio's value of 0.99 is 518.8% above this industry median. Based on the distribution chart, Nuvation Bio ranks #845 out of 962 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Nuvation Bio has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Nuvation Bio's Debt-to-Equity compare to RAPP and BHVN?
According to the Biotechnology industry distribution chart, Nuvation Bio ranks #845 out of 962 companies for Debt-to-Equity. This places Nuvation Bio in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Nuvation Bio's value of 0.99 is 518.8% above this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.16, Nuvation Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nuvation Bio's current Debt-to-Equity of 0.99 is 518.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nuvation Bio and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nuvation Bio's current Debt-to-Equity is 0.99, which is 9800% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuvation Bio stock overvalued right now?
Nuvation Bio (NUVB) has a current Debt-to-Equity of 0.99. The current Debt-to-Equity is 0.99, which is 9800% above median its 10-year median of 0.01 and 518.8% above the Biotechnology industry median of 0.16. Nuvation Bio's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nuvation Bio (NUVB), the current Debt-to-Equity is 0.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
32GF Score
Get the complete analysis for NUVB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUVB has been successfully added to your 
